Stock is consolidating above R4 camarilla levels in weekly time frame.
It has come out of a big consolidation. It is consistently paying dividends and is trading at a very attractive PE multiple.
It seems buying this is like buying biopharmaceuticals portfolio. Not betting on a single biopharmaceutical stock but a company which is buying royalties and is funder of innovations. This should be more than enough diversification in single holding.
It is having very relevant portfolio for current geopolitical situation.
I think, 42$ would be fair value from technical analysis and intrinsic value should be around 80$.
YoY EPS need to cross 5.08 levels before the 80 levels get realized rapidly as there shall be QoQ earnings growth acceleration. Till then conservative view of 40$ to 42$.
It has come out of a big consolidation. It is consistently paying dividends and is trading at a very attractive PE multiple.
It seems buying this is like buying biopharmaceuticals portfolio. Not betting on a single biopharmaceutical stock but a company which is buying royalties and is funder of innovations. This should be more than enough diversification in single holding.
It is having very relevant portfolio for current geopolitical situation.
I think, 42$ would be fair value from technical analysis and intrinsic value should be around 80$.
YoY EPS need to cross 5.08 levels before the 80 levels get realized rapidly as there shall be QoQ earnings growth acceleration. Till then conservative view of 40$ to 42$.
Penafian
Maklumat dan penerbitan adalah tidak dimaksudkan untuk menjadi, dan tidak membentuk, nasihat untuk kewangan, pelaburan, perdagangan dan jenis-jenis lain atau cadangan yang dibekalkan atau disahkan oleh TradingView. Baca dengan lebih lanjut di Terma Penggunaan.
Penafian
Maklumat dan penerbitan adalah tidak dimaksudkan untuk menjadi, dan tidak membentuk, nasihat untuk kewangan, pelaburan, perdagangan dan jenis-jenis lain atau cadangan yang dibekalkan atau disahkan oleh TradingView. Baca dengan lebih lanjut di Terma Penggunaan.